Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.

Abstract: A pharmaceutical composition and methods of administering the same for treatment of cardiovascular disease comprising a pepducin having a sequence SEQ ID No. 1, wherein said composition stimulates cardiomyocyte contractility and activating the ?2AR/?-arrestin signaling pathway.

Abstract: A functionalized tissue having covalently bound antibiotics and methods for producing the functionalized tissue having bound antibiotics comprising; providing a tissue having a sufficient number of primary amine groups on the tissue; coupling and deprotecting one or more F-moc AEEA linkers using HATU chemistry to the primary amine groups; and coupling an antibiotic to said AEEA linkers using HATU chemistry.

Abstract: Embodiments disclosed herein provide for methods of treating cancer and detecting CCR5 on circulating tumor cells and uses thereof based upon the same.

Abstract: A substance of Formula (I) for use as a medicament for the treatment of cardiovascular diseases, wherein R is nitrogen or carbon; R1 is selected from the group consisting of a hydrogen, a trifluoromethyl, a methyloxyphenyl, a phenyl, a C1-C3 phenylalkyl, a halogenated phenyl, a halogenated C1-C3 phenylalkyl, a trifluoromethyloxy, a trifluoromethyl oxyphenyl, and a C1-C3 pyridinylalkyl; R2 is selected from the group consisting of a C1-C3 alkyl alcohol optionally substituted with a C1-C3 alkoxyphenyl, a C1-C3 N-alkylmethanamine, a C1-C3 alkoxymethyl, a C1-C3 phenylalkoxymethyl, a C1-C3 cyclopropylalkoxymethyl, and a methoxyethoxymethyl; and R3 is a phenyl or a methoxypyridinyl; and R4 is selected from the group consisting of a hydrogen, a cyano, a C1-C3 sulfonyl, a nitro, and a trifluoromethyl.

Abstract: This invention provides a method of identifying one or more subgroups of cancer patients that are likely to benefit from treatment with a monocarboxylate transporter (MCT) protein inhibitor comprising: (a) obtaining a sample of a cancer/tumor tissue from each of said cancer patients; (b) determining the expression level of stromal MCT4 protein in each of said samples of cancer/tumor tissue to obtain a first dataset; and (c) using the expression level of the stromal MCT4 protein from said first dataset to classify each of said sets of one or more cancer patients as stromal MCT4-positive or stromal MCT4-negative, wherein the cancer patients classified as stromal MCT4-positive are patients that are more likely to benefit from treatment with said MCT protein inhibitor. This invention also provides related methods for treating a cancer/tumor whose stromal component expresses the MCT4 protein in a patient.

Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.

Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.

Abstract: A method for specifically and efficiently quantify the expression of targeted RNA variants with specific terminal sequences suitable to identify multiple isoforms bearing complex heterogeneity in terminal sequences by hybridizing a 5?-Dbs-adapter to the 5?-end of target RNAs, wherein the 5?-Dbs-adapter has a stem-loop structure whose protruding 5?-end base-pairs 5?-end of target RNAs, and wherein the loop region of 5?-Dbs-adapter contains a base-lacking spacer which will terminate reverse transcription in a subsequent step; hybridizing a 3?-Db-adapter to the 3?-end of target RNAs, wherein the 3?-Db-adapter has a stem-loop structure whose protruding 3?-end base-pairs 3?-end of target RNAs; ligating the both adapters with target RNAs by Rnl2 ligation to form “dumbbell-like” structure; and, amplifying and quantifying the ligation product by TaqMan RT-PCR.

Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.

Abstract: A sanitation system may include a sink, a sanitation material dispenser for dispensing material such as soap, and a dryer for either dispensing dryer material such as paper towels or providing heated air. An electronic device may be in communication with one or more of these items, and a sanitation module may operate on the sanitation system. The sanitation module may time a sanitation activity for the sanitation system, such as hand washing. Content may be displayed on the electronic device, and the content may serve to engage or distract the user. The electronic device may be able to identify the individual user and customize the content. The sanitation module may time the sanitation procedure and may accordingly promote a minimum time spent on the sanitation activity. The sanitation system may also be used for monitoring either the sanitation material or the dryer material and automatically order new material when the material is low.

Abstract: A composition of matter comprising an adeno-associated virus (AAV) or other human compatible virus, encoding the gene for Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof, and a neuron specific promoter, wherein the composition is suitable for administration to a patient comprising injecting the AAV or other human compatible virus into the brain by intracranial stereotaxic injunction; wherein the AAV's encoding for the Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof enhance and/or normalize levels of GM1 in neurons, providing both therapeutic relief and disease modifying effects in specific areas of the brain relevant to particular neurodegenerative diseases.

Abstract: Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).

Abstract: A continuous subcutaneous infusion catheter includes an elongate flexible cannula and a plurality of holes through the cannula wall that are positioned both along the axial length of the cannula and radially around the cannula. The proximal end of the cannula is configured to be attached to a pump, and the distal end of the flexible cannula is atraumatic. The catheter can be used to deliver insulin to a patient.

Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.

Abstract: In accordance with one embodiment, a device for performing an angled craniotome includes an elongate handle, a footplate, a stem, and an elongate cutting bit. The elongate handle extends in a vertical direction. The footplate is spaced apart from the elongate handle and defines a plane generally perpendicular to the vertical direction. The footplate is offset from the handle in a horizontal direction where the horizontal direction is perpendicular to the vertical direction. The stem has a proximal end and a distal end. The proximal end is coupled to the handle and the distal end is coupled to the footplate. The stem extends from the handle at an oblique angle in the horizontal direction relative to the handle. The elongate cutting bit is coupled to the handle and extends from the handle toward the footplate at the oblique angle in the horizontal direction relative to the handle.

Abstract: This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject's glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject's glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject's glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide.

Abstract: A hypodermic injection device configured to be attached to a portable electronic device is disclosed herein. The hypodermic injection device can be an auto-injector for delivering a dose of an injectable medicament. The injection device can include a durable barrier providing a sheath over an injectable cannula to maintain sterility of an injectable cannula that delivers the medicament. The injection device can also include tamper proof features such as by requiring that deployment of the device only be possible after completing two mechanical manipulations so as to prevent accidental discharge of the injection device. By incorporating the injection device within a case for a portable electronic device, the injection device is readily available to those that rely on auto-injectors to provide emergency therapeutic treatment, and is much less likely to be forgotten or left behind by a user than a typical auto-injector.

Abstract: A method for providing perihematomal protection to a patient after suffering an ICH comprising administering an effective amount of Hx to said patient to increase serum concentrations to between two and three times normal serum levels, wherein said increased serum concentrations are maintained for between 3 and 21 days.

Abstract: A method for detecting and quantifying of the frequency of T cells to multiple antigenic peptide epitopes comprising: measuring intracellular Ca2+ signaling in individual T cells that are labeled with Ca2+ sensitive fluorophore; wherein said T cells are placed on the glass bottom of a well-covered with antibodies or other capturing proteins specific for non-stimulatory T cells' surface receptors and wherein a peptide antigens are injected into the well and the peptide binds to MHC molecules on the T-cell surface, wherein an increase in the intracellular concentration of Ca2+ in responding T cells leads to rise in intracellular fluorescence that is detected by fluorescent microscope and wherein the response rate of said detected fluorescence can be utilized to determine the quantity of responding T cells and the efficiency of said cells.